{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T03:35:33Z","timestamp":1789011333391,"version":"build-2803163510"},"reference-count":17,"publisher":"American Society of Hematology","issue":"18","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,9,28]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Multiple myeloma (MM) is a heterogeneous disease that has an increased incidence in African Americans (AAs). We previously observed that, with equal access to health care, younger AA patients (age &amp;lt; 65 years) have superior overall survival (OS) compared with younger White patients. Because MM prognosis is influenced by 17p deletion (del17p), we investigated racial differences in its occurrence and impact in a large cohort of MM patients from the Veterans Affairs (VA) system. Among 2243 VA patients with MM for whom del17p data were available, del17p was present in 8.83% of all patients, with a significantly lower prevalence in AAs (5.56%) compared with Whites (10.52%; P &amp;lt; .001). The difference was even more pronounced among younger AAs (&amp;lt;65 years) vs younger Whites (4.34% vs 9.8%, respectively; P = .004). However, we did not observe any significant difference in survival between AA and White patients with del17p, regardless of age category, suggesting that del17p carries a poor prognosis across race and age. Interestingly, among patients without del17p, we still noted a significantly superior OS in younger AAs compared with younger Whites (7.75 vs 5.10 years; P = .042). Our study shows a lower incidence of del17p in AAs but suggests that the survival advantage for younger AAs is primarily due to factors other than del17p.<\/jats:p>","DOI":"10.1182\/bloodadvances.2020004001","type":"journal-article","created":{"date-parts":[[2021,8,24]],"date-time":"2021-08-24T18:58:15Z","timestamp":1629831495000},"page":"3511-3514","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":12,"title":["Lack of differential impact of del17p on survival in African Americans compared with White patients with multiple myeloma: a VA study"],"prefix":"10.1182","volume":"5","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8058-3423","authenticated-orcid":false,"given":"Nathanael R.","family":"Fillmore","sequence":"first","affiliation":[{"name":"VA Boston Healthcare System, Boston, MA;"},{"name":"Department of Medicine, Harvard Medical School, Boston, MA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana","family":"Cirstea","sequence":"additional","affiliation":[{"name":"Dana-Farber Cancer Institute, Boston, MA;"},{"name":"Department of Medicine, Harvard Medical School, Boston, MA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anusha","family":"Munjuluri","sequence":"additional","affiliation":[{"name":"VA Boston Healthcare System, Boston, MA;"},{"name":"Dana-Farber Cancer Institute, Boston, MA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hassan","family":"Yameen","sequence":"additional","affiliation":[{"name":"St. Joseph Hospital, Nashua, NH;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarvari V.","family":"Yellapragada","sequence":"additional","affiliation":[{"name":"Michael E. DeBakey VA Medical Center, Houston, TX;"},{"name":"Department of Medicine, Dan L. Duncan Cancer Center, Baylor College of Medicine, Houston, TX; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nhan V.","family":"Do","sequence":"additional","affiliation":[{"name":"VA Boston Healthcare System, Boston, MA;"},{"name":"Boston University School of Medicine, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary T.","family":"Brophy","sequence":"additional","affiliation":[{"name":"VA Boston Healthcare System, Boston, MA;"},{"name":"Boston University School of Medicine, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raphael E.","family":"Szalat","sequence":"additional","affiliation":[{"name":"VA Boston Healthcare System, Boston, MA;"},{"name":"Boston University School of Medicine, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikhil C.","family":"Munshi","sequence":"additional","affiliation":[{"name":"VA Boston Healthcare System, Boston, MA;"},{"name":"Department of Medicine, Harvard Medical School, Boston, MA;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2021,9,17]]},"reference":[{"issue":"2","key":"2021091715292849700_B1","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1038\/s41408-019-0177-9","article-title":"Molecular underpinnings of clinical disparity patterns in African American vs. Caucasian American multiple myeloma patients","volume":"9","author":"Kazandjian","year":"2019","journal-title":"Blood Cancer J."},{"issue":"39","key":"2021091715292849700_B2","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1200\/EDBK_238551","article-title":"Many shades of disparities in myeloma care","volume":"39","author":"Ganguly","year":"2019","journal-title":"Am Soc Clin Oncol Educ Book."},{"issue":"1","key":"2021091715292849700_B3","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21551","article-title":"Cancer statistics, 2019","volume":"69","author":"Siegel","year":"2019","journal-title":"CA Cancer J Clin."},{"issue":"3","key":"2021091715292849700_B4","doi-asserted-by":"crossref","first-page":"211","DOI":"10.3322\/caac.21555","article-title":"Cancer statistics for African Americans, 2019","volume":"69","author":"DeSantis","year":"2019","journal-title":"CA Cancer J Clin."},{"issue":"10","key":"2021091715292849700_B5","doi-asserted-by":"crossref","first-page":"e618","DOI":"10.1038\/bcj.2017.97","article-title":"Prevalence of myeloma precursor state monoclonal gammopathy of undetermined significance in 12372 individuals 10-49 years old: a population-based study from the National Health and Nutrition Examination Survey","volume":"7","author":"Landgren","year":"2017","journal-title":"Blood Cancer J."},{"issue":"10","key":"2021091715292849700_B6","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1038\/s41408-018-0132-1","article-title":"Differences in genomic abnormalities among African individuals with monoclonal gammopathies using calculated ancestry","volume":"8","author":"Baughn","year":"2018","journal-title":"Blood Cancer J."},{"issue":"10","key":"2021091715292849700_B7","doi-asserted-by":"crossref","first-page":"4235","DOI":"10.1182\/blood-2007-10-119123","article-title":"An analysis of the clinical and biologic significance of TP53 loss and the identification of potential novel transcriptional targets of TP53 in multiple myeloma","volume":"112","author":"Xiong","year":"2008","journal-title":"Blood."},{"issue":"11","key":"2021091715292849700_B8","doi-asserted-by":"crossref","first-page":"4569","DOI":"10.1182\/blood-2002-10-3017","article-title":"Clinical and biologic implications of recurrent genomic aberrations in myeloma","volume":"101","author":"Fonseca","year":"2003","journal-title":"Blood."},{"issue":"8","key":"2021091715292849700_B9","doi-asserted-by":"crossref","first-page":"3489","DOI":"10.1182\/blood-2006-08-040410","article-title":"Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du My\u00e9lome","volume":"109","author":"Avet-Loiseau","year":"2007","journal-title":"Blood."},{"issue":"26","key":"2021091715292849700_B10","doi-asserted-by":"crossref","first-page":"2863","DOI":"10.1200\/JCO.2015.61.2267","article-title":"Revised International Staging System for Multiple Myeloma: a report from International Myeloma Working Group","volume":"33","author":"Palumbo","year":"2015","journal-title":"J Clin Oncol."},{"issue":"6","key":"2021091715292849700_B11","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1002\/ajh.25098","article-title":"Treatment patterns and clinical outcomes in high-risk newly diagnosed multiple myeloma patients carrying the 17p deletion: an observational multi-center retrospective study","volume":"93","author":"Cohen","year":"2018","journal-title":"Am J Hematol."},{"issue":"24","key":"2021091715292849700_B12","doi-asserted-by":"crossref","first-page":"2615","DOI":"10.1182\/blood.2019000406","article-title":"With equal access, African American patients have superior survival compared to white patients with multiple myeloma: a VA study","volume":"133","author":"Fillmore","year":"2019","journal-title":"Blood."},{"issue":"8","key":"2021091715292849700_B13","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1182\/bloodadvances.2019001411","article-title":"Vitamin D deficiency predicts for poor overall survival in white but not African American patients with multiple myeloma","volume":"4","author":"Yellapragada","year":"2020","journal-title":"Blood Adv."},{"issue":"16","key":"2021091715292849700_B14","doi-asserted-by":"crossref","first-page":"3147","DOI":"10.1182\/blood-2012-07-443606","article-title":"Uncovering the biology of multiple myeloma among African Americans: a comprehensive genomics approach","volume":"121","author":"Baker","year":"2013","journal-title":"Blood."},{"issue":"11","key":"2021091715292849700_B15","doi-asserted-by":"crossref","first-page":"e1007087","DOI":"10.1371\/journal.pgen.1007087","article-title":"Comprehensive molecular profiling of 718 multiple myelomas reveals significant differences in mutation frequencies between African and European descent cases","volume":"13","author":"Manojlovic","year":"2017","journal-title":"PLoS Genet."},{"issue":"9","key":"2021091715292849700_B16","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1182\/blood.2020008346","article-title":"del(17p) without TP53 mutation confers a poor prognosis in intensively treated newly diagnosed patients with multiple myeloma","volume":"137","author":"Corre","year":"2021","journal-title":"Blood."},{"issue":"11","key":"2021091715292849700_B17","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1182\/blood-2018-10-880831","article-title":"High subclonal fraction of 17p deletion is associated with poor prognosis in multiple myeloma","volume":"133","author":"Thakurta","year":"2019","journal-title":"Blood."}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/5\/18\/3511\/1822599\/advancesadv2020004001.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/5\/18\/3511\/1822599\/advancesadv2020004001.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,17]],"date-time":"2021-09-17T15:30:01Z","timestamp":1631892601000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/5\/18\/3511\/476659\/Lack-of-differential-impact-of-del17p-on-survival"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,24]]},"references-count":17,"journal-issue":{"issue":"18","published-print":{"date-parts":[[2021,9,28]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2020004001","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,24]]}}}